| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | MLC2; CMH10; DKFZp779C0562 |
| Entrez GeneID | 4633 |
| clone | 7C9 |
| WB Predicted band size | 19kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of MYL2 expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是3篇与SLC2A2(GLUT2)抗体相关的文献示例(内容基于学术研究的常见方向，非真实文献)：
---
1. **文献名称**: "Antibody-based detection of SLC2A2/GLUT2 in pancreatic β-cells reveals reduced expression in type 2 diabetes models"
**作者**: Martinez, A. et al.
**摘要**: 通过免疫组化和Western blot分析，验证了SLC2A2抗体在小鼠及人类胰腺β细胞中的特异性，发现高糖饮食诱导的糖尿病模型中GLUT2蛋白表达显著下调，提示其与胰岛素分泌功能障碍相关。
---
2. **文献名称**: "Validation of a novel anti-SLC2A2 monoclonal antibody for renal proximal tubule glucose transport studies"
**作者**: Chen, L. & Yamamoto, K.
**摘要**: 研究报道了一种新型单克隆抗体的开发及验证，该抗体可特异性识别肾脏近端小管细胞中的SLC2A2蛋白。通过基因敲除小鼠模型证实抗体特异性，并用于揭示高血糖条件下GLUT2膜定位异常的现象。
---
3. **文献名称**: "SLC2A2 antibody reveals dynamic expression patterns in zebrafish liver development"
**作者**: Gupta, R. et al.
**摘要**: 利用斑马鱼模型结合SLC2A2抗体进行免疫荧光分析，发现GLUT2在肝脏发育早期阶段表达逐渐增强，且与肝细胞分化成熟密切相关，为研究代谢器官发育提供了工具。
---
4. **文献名称**: "Comparative analysis of commercial SLC2A2 antibodies highlights variability in specificity for metabolic studies"
**作者**: Smith, J.D. et al.
**摘要**: 系统性评估了5种市售SLC2A2抗体的特异性，发现部分抗体存在非特异性结合问题。通过siRNA敲低实验推荐了两种可靠抗体，强调抗体验证在肝脏和肠道GLUT2定量研究中的必要性。
---
(注：以上文献为示例性内容，实际研究中请通过数据库如PubMed检索真实文献。)
The SLC2A2 antibody targets the solute carrier family 2 member 2 (SLC2A2) protein, also known as glucose transporter type 2 (GLUT2). Encoded by the SLC2A2 gene, GLUT2 is a facilitative transmembrane transporter responsible for glucose uptake and release across cell membranes. It is predominantly expressed in metabolically active tissues, including the liver, pancreatic β-cells, kidneys, and small intestine, where it plays a critical role in glucose homeostasis. GLUT2 facilitates bidirectional transport of glucose, enabling cells to respond dynamically to blood glucose levels. Dysregulation of SLC2A2/GLUT2 is linked to metabolic disorders such as type 2 diabetes, Fanconi-Bickel syndrome (a rare glycogen storage disease), and certain cancers.
SLC2A2 antibodies are essential tools for studying the expression, localization, and function of GLUT2 in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to analyze tissue-specific expression patterns or alterations in disease models. Commercial SLC2A2 antibodies are typically raised against specific epitopes of the human or rodent GLUT2 protein and are available as monoclonal or polyclonal variants. Researchers rely on these antibodies to explore GLUT2's role in insulin secretion, renal glucose reabsorption, and intestinal sugar absorption, providing insights into therapeutic strategies for diabetes and related metabolic conditions. Validation of antibody specificity remains crucial to ensure accurate experimental outcomes.
×
